VIA
NGNE icon

Virtus Investment Advisers’s Neurogene NGNE Stock Holding History

Virtus Investment Advisers’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$354K Sell
11,244
-1,789
-14% -$49.3K 0.08% 344
2026
Q1 		$263K Buy
13,033
+317
+2% +$6.14K 0.07% 305
2025
Q4 		$262K Buy
12,716
+7,138
+128% +$178K 0.07% 307
2025
Q3 		$96.7K Buy
5,578
+969
+21% +$19.5K 0.03% 427
2025
Q2 		$68.9K Sell
4,609
-2,742
-37% -$43K 0.02% 435
2025
Q1 		$86.1K Buy
+7,351
New +$128K 0.02% 442

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Virtus Investment Advisers's NGNE Position: Q2 2026 in Review

Virtus Investment Advisers reduced its Neurogene (NGNE) stake by 14% in Q2 2026, selling an estimated $49.3K and leaving 11,244 shares worth $354K. The position accounts for 0.08% of the portfolio, ranked #344.

Virtus Investment Advisers first reported a position in NGNE in Q1 2025 and has held it in 6 quarters since. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Virtus Investment Advisers held 11,244 shares of Neurogene worth $354K as of Q2 2026.
  • Virtus Investment Advisers sold 1,789 Neurogene shares in Q2 2026, an estimated $49.3K.
  • Neurogene made up 0.08% of Virtus Investment Advisers's portfolio in Q2 2026, its #344 holding.
  • Virtus Investment Advisers first reported a position in Neurogene in Q1 2025 and has held it in 6 quarters since.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.